Ysebaert Loic, Quillet-Mary Anne, Tosolini Marie, Pont Frederic, Laurent Camille, Fournié Jean-Jacques
Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
Front Immunol. 2021 Feb 26;12:597651. doi: 10.3389/fimmu.2021.597651. eCollection 2021.
High-definition transcriptomic studies through single-cell RNA sequencing (scRNA-Seq) have revealed the heterogeneity and functionality of the various microenvironments across numerous solid tumors. Those pioneer studies have highlighted different cellular signatures correlated with clinical response to immune checkpoint inhibitors. scRNA-Seq offers also a unique opportunity to unravel the intimate heterogeneity of the ecosystems across different lymphoma entities. In this review, we will first cover the basics and future developments of the technology, and we will discuss its input in the field of translational lymphoma research, from determination of cell-of-origin and functional diversity, to monitoring of anti-cancer targeted drugs response and toxicities, and how new improvements in both data collection and interpretation will further foster precision medicine in the upcoming years.
通过单细胞RNA测序（scRNA-Seq）进行的高清转录组学研究揭示了多种实体瘤中不同微环境的异质性和功能。这些开创性研究突出了与免疫检查点抑制剂临床反应相关的不同细胞特征。scRNA-Seq还提供了一个独特的机会，来揭示不同淋巴瘤实体中生态系统的内在异质性。在这篇综述中，我们将首先介绍该技术的基础知识和未来发展，并讨论其在转化性淋巴瘤研究领域的作用，从确定细胞起源和功能多样性，到监测抗癌靶向药物的反应和毒性，以及数据收集和解释方面的新改进将如何在未来几年进一步推动精准医学的发展。
